Edgewise rated as a new Hold at Stifel on a balanced risk-reward setup
Edgewise Therapeutics (EWTX) stock traded flat as Stifel launched its coverage with a Hold recommendation, indicating a ...
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Short Interest Up 8.9% in December
Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Get Free Report) was the target of a significant growth in short interest during ...
Hosted on MSN1d
Stifel Initiates Coverage of Edgewise Therapeutics (EWTX) with Hold Recommendation
Fintel reports that on January 22, 2025, Stifel initiated coverage of Edgewise Therapeutics (NasdaqGS:EWTX) with a Hold ...
Edgewise Therapeutics: Strategic Positioning and Promising Clinical Advancements Support Buy Rating
Leerink Partners analyst Joseph Schwartz has maintained their bullish stance on EWTX stock, giving a Buy rating yesterday.Stay Ahead of the ...
Edgewise Therapeutics promotes Behrad Derakhshan to COO
Edgewise Therapeutics (EWTX) announced changes to its executive team. These changes include the addition of Robert Blaustein, joining the ...
Stockhouse10d
Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025
Ph.D., President and Chief Executive Officer of Edgewise Therapeutics. “Additionally, we are thrilled with initial results from EDG-7500 in patients with obstructive hypertrophic cardiomyopathy and ...
Business Wire1mon
Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)
--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive topline results from the Phase 2 CANYON trial of ...
Business Wire10d
Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025
--(BUSINESS WIRE)--Edgewise Therapeutics ... with obstructive hypertrophic cardiomyopathy and look forward to sharing additional, longer-term data across HCM populations in 2025.” ...